Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Takara Bio Inc. ( (JP:4974) ) has shared an update.
Takara Bio Inc. has resolved at its board meeting to cancel all of its treasury stock, consisting of 300 common shares out of a total 120,415,600 issued shares, under Japan’s Companies Act. The cancellation is scheduled for June 15, 2026, and is contingent on shareholder approval of a planned share consolidation to take effect the following day.
While the number of treasury shares is small relative to the total shares outstanding, the move is part of a broader capital structure adjustment around the share consolidation. The decision underscores management’s effort to simplify the company’s equity base, which may marginally improve capital efficiency and clarify the share count for investors ahead of the planned changes.
The most recent analyst rating on (JP:4974) stock is a Hold with a Yen940.00 price target. To see the full list of analyst forecasts on Takara Bio Inc. stock, see the JP:4974 Stock Forecast page.
More about Takara Bio Inc.
Takara Bio Inc., listed on the Tokyo Stock Exchange Prime section, operates in the biotechnology and life sciences sector, providing products and technologies that support research and biopharmaceutical development. The company serves a global market of academic, clinical, and industrial customers seeking advanced genetic and cellular tools.
Average Trading Volume: 711,003
Technical Sentiment Signal: Sell
Current Market Cap: Yen137.6B
Learn more about 4974 stock on TipRanks’ Stock Analysis page.